Murex granted approval for five latex agglutination tests:
This article was originally published in Clinica
International Murex has launched five latex agglutination tests in the US following FDA approval. The kits detect antibodies to infectious mononucleosis, group A streptococcus, rheumatoid arthritis and C-reactive protein. The tests will be marketed to clinical reference and hospital laboratories. The company estimates the collective US market for these tests at around $20 million. The tests provide results in between two and ten minutes, says Murex.